



Markets
/
Stocks
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

View Detailed Chart

251.560USD

+8.949+3.69%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

32.53BMarket Cap

LossP/E TTM



Alnylam Pharmaceuticals Inc

251.560

+8.949+3.69%

Company

Intraday

30m

Today

+3.69%

5 Days

+7.25%

1 Month

+3.77%

6 Months

-11.69%

Year to Date

+6.91%

1 Year

+75.54%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 33 analysts

BUY

Current Rating

317.821

Target Price

26.34%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

Alnylam Pharmaceuticals Inc

ALNY

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(3)

Neutral(2)

Buy(6)

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

3.928

Neutral

RSI(14)

55.595

Neutral

STOCH(KDJ)(9,3,3)

85.418

Buy

ATR(14)

15.593

Low Volatility

CCI(14)

187.986

Buy

Williams %R

3.567

Overbought

TRIX(12,20)

-0.224

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

241.128

Buy

MA10

237.941

Buy

MA20

240.395

Buy

MA50

251.566

Sell

MA100

250.222

Buy

MA200

256.703

Sell

News

More news coming soon, stay tuned...

Company

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Company codeALNY

CompanyAlnylam Pharmaceuticals Inc

CEODr. Yvonne L. Greenstreet, M.D.

Websitehttps://www.alnylam.com/